NeuroSense CMO reports options and warrants

NeuroSense Therapeutics Ltd. Chief Medical Officer Tracik Ferenc filed a Form 3 disclosing his existing equity stake in the company.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. Chief Medical Officer Tracik Ferenc filed a Form 3 disclosing his existing equity stake in the company. The filing lists fully vested options to purchase 108,000 Ordinary Shares at an exercise price of $3.51 per share, expiring on October 31, 2031, and warrants to purchase 66,667 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029. It also notes direct holdings of Ordinary Shares and includes restricted shares that vest in 2027 or earlier upon achieving a specified business milestone.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Tracik Ferenc

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Warrants to purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 108,000 contracts (Direct); Warrants to purchase Ordinary Shares — 66,667 contracts (Direct); Ordinary Shares — 617,629 shares (Direct)

Footnotes (3)

F1. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F2. These options are fully vested and exercisable.
F3. On August 15, 2024, the Reporting Person acquired (i) 66,667 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,667 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NeuroSense Therapeutics (NRSN) Form 3 by Tracik Ferenc report?

The Form 3 reports Chief Medical Officer Tracik Ferenc’s existing equity holdings in NeuroSense Therapeutics. It outlines his options, warrants, ordinary shares, and restricted share awards as of the reporting date, giving a snapshot of his current ownership position in the company.

How many NeuroSense (NRSN) options does Tracik Ferenc hold on this Form 3?

The filing shows fully vested options to purchase 108,000 Ordinary Shares at an exercise price of $3.51 per share, expiring October 31, 2031. These options are currently exercisable, providing potential future share ownership if he chooses to exercise them.

What warrant holdings are disclosed for NeuroSense (NRSN) CMO in the Form 3?

The Form 3 lists warrants to purchase 66,667 Ordinary Shares at an exercise price of $0.75 per share, expiring August 14, 2029. A footnote explains these warrants, and 66,667 Ordinary Shares, were acquired together in a private placement on August 15, 2024.

Are any of Tracik Ferenc’s NeuroSense (NRSN) shares subject to vesting conditions?

Yes. The filing notes restricted shares that vest 75% on April 16, 2027, and the remainder on October 16, 2027. Vesting requires continued service, with potential acceleration if a specified business milestone in the restricted share agreement is achieved.

Does this NeuroSense (NRSN) Form 3 show any new insider buying or selling activity?

No new buy or sell transactions are reported. The entries are characterized as holdings, and the transaction summary shows zero buys, zero sells, and only holding entries, indicating disclosure of existing positions rather than recent trading activity.

What prior transaction is referenced in the NeuroSense (NRSN) Form 3 footnotes?

A footnote states that on August 15, 2024, Tracik Ferenc acquired 66,667 Ordinary Shares and warrants to purchase 66,667 Ordinary Shares at a combined purchase price of $0.75 per share and accompanying warrant in a private placement exempt from Securities Act registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 03:36 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tracik Ferenc

(Last)

(First)

(Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA

4672562

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	189,618	D
Ordinary Shares⁽¹⁾	428,011⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options to Purchase Ordinary Shares⁽²⁾	03/13/2022	10/31/2031	Ordinary Shares	108,000⁽²⁾	$3.51	D
Warrants to purchase Ordinary Shares⁽³⁾	08/15/2024	08/14/2029	Ordinary Shares	66,667⁽³⁾	$0.75	D

Explanation of Responses:

1. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

2. These options are fully vested and exercisable.

3. On August 15, 2024, the Reporting Person acquired (i) 66,667 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,667 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

	/s/ Ferenc Tracik	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR